A Chinese medical-industry research group recently published an eight-dimension deep analysis of a single news event: former U.S. President Joe Biden's prostate cancer has worsened, and the disease has spread to bone and other organs. The document is remarkable for one reason. Five of its eight dimensions return a polite N/A. The remaining three are stamped medium or low confidence. The analysts explain, almost apologetically, that they have no drug names, no Gleason score, no PSA doubling time, no PSMA-PET imaging, no treatment history — and rather than invent a story from the void, they say so in writing. That should be unremarkable; it is the most honest piece of industry analysis I have read in years. Because I have read a thousand crypto deep dives in the past eight years, and I cannot recall a single one built on that kind of integrity.
Some background on the underlying disease. Prostate cancer with bone and visceral spread is almost certainly metastatic castration-resistant prostate cancer, or mCRPC. Oncology has industrialized this stage: androgen-deprivation therapy, next-generation hormone agents like abiraterone and enzalutamide, taxane chemotherapy, PARP inhibitors for BRCA/HRR-mutant disease, bone-targeted agents, and the radiopharmaceutical Pluvicto. The global market is tens of billions of dollars. The analysts knew all of this intimately — and still refused to map it onto the patient, because the individual facts that would justify the map simply do not exist.
That discipline matters to us because the framework the medical team used is almost exactly the template a crypto research desk applies to a token project. Product assessment maps to protocol architecture, regulation to securities-law exposure, commercialization to token utility, competition to other L1s and DEXs. Clinical need and market space maps to total addressable market and adoption metrics. The metric system is different; the structure of the inquiry is the same. And the failures are the same — except in one crucial respect. The medical report is honest about its failures.
The report also ranks its top risks, and the first line is a punch to the gut. Information authenticity cannot be verified, it says — high severity, high probability — and the recommended response is to treat the story as unconfirmed rumor until an independent official source appears. I have never seen a crypto research report open with that assessment. A founder's sudden illness, a wallet drain, a politician's overnight tweet — all of it gets priced in as fact in real time. The medical team priced the rumor as a rumor, and that alone made them sophisticated.
I spent DeFi Summer 2020 auditing Uniswap V2 liquidity pools — 150 contracts in three months. I found a slippage edge case that exposed roughly $2 million in user funds. The bug was not in anything the pool advertised. It lived in information that was not disclosed: the reserve depth, the sandwiching pressure, the gap between quoted and executed price under stress. That lesson stayed with me. A framework that only scores what it can see is not an analysis. It is a brochure.
Consider the first dimension. The medical report says, in effect: no disclosed product, therefore no product assessment. In crypto, we routinely evaluate the product potential of protocols with unaudited code, anonymous teams, and phantom testnets. The report's refusal to assess the unassessable would be called unhelpful negativity inside our industry. — Root: we treat disclosure as a courtesy instead of a precondition, and analysis as a substitute for information rather than a response to it.
The regulatory dimension returns a polite N/A because no drug was named. The report flags one signal worth keeping: an unapproved therapy would route through compassionate use or a trial. In crypto, the comparable situation is a senator's tweet about a bill — a rumor that is not a statute, a court filing that is not a verdict. Yet we produce regulatory-path reports from such crumbs daily. The report's refusal to speculate is the professional response.
Then there is the hidden-information table. The medical analysts listed precisely what they needed and did not have: treatment line, BRCA/HRR mutation status, PSMA expression, PSA velocity. In crypto, the equivalent list would be: team track record, distribution schedule, unlock calendar, LP concentration, audit scope. The hidden-information genre does not exist in crypto research reports. Every report presents missing data as neutral background instead of a glaring unpaid debt. The medical report frames it correctly: if PSMA expression is negative, Pluvicto is inapplicable. One missing biomarker flips the entire treatment paradigm. One missing unlock date flips an entire risk profile. Nobody prints that table.
The confidence scoring should be tattooed onto every research desk. The report separates confidence in the medical consensus — mCRPC is well-characterized, the epidemiology is known — from confidence in the individual case, which is effectively zero. Crypto never makes that split. We take a macro narrative — DeFi is the future, Bitcoin is digital gold, stablecoins will replace payment rails — and apply it with false precision to individual protocols. Liquidity isn't understanding. A $200 million pool does not validate a risk model; it measures attention.
As a historical note: when Angelina Jolie disclosed her BRCA mutation, genetic-testing demand spiked measurably. Celebrity illness changes behavior; it rarely changes product economics. The same law governs crypto. A celebrity endorsement spikes on-chain activity, a politician's diagnosis redirects attention, and the underlying infrastructure is untouched. We mine liquidity from attention and call it fundamentals. The medical analysts would call that a category error.
The only dimension where the report speaks with real confidence is clinical need and market space — because that analysis is grounded in verifiable aggregates: 290,000 new U.S. prostate-cancer cases per year, 60,000 to 80,000 new mCRPC patients annually, a quantified unmet need, an entrenched payment pathway. We have extraordinary transparency at the transaction layer and almost no grounded analysis at the adoption layer. We can tell you which wallet moved which token at which block. We cannot reliably tell you how many real users depend on a protocol for something non-speculative. That asymmetry is the industry's quiet scandal.
The report also notes that HRR/BRCA testing is in the guidelines but underutilized in practice — if the former president's physicians have not run it, they are behind standard of care. On-chain, the equivalent standard is a recent audit and a transparent deployment. Most projects fail even that low bar. Know the biomarker before choosing the therapy. Verify the contract before committing the capital. The sentence works in both languages.
After the 2022 crash, I lost my startup funding. I spent six months maintaining the Gnosis Safe multisig, submitting forty-odd patches to the repository — wallet logic, recovery paths, edge-case reverts. Boring work. It rebuilt me. The infrastructure demand was real even when the narrative was dead. That is the equivalent of mCRPC epidemiology: the patients are there whether or not the hype cycle is. Crypto's actual market space is the plumbing demand, the audit demand, the settlement demand — and almost nobody publishes that number because it is not exciting.
Now the counter-intuitive turn. We didn't build a future; we built a mirror. The medical report's N/A verdicts are a luxury of a mature information culture: a discipline can say this news changes nothing. Crypto's attention economy structurally cannot afford that answer, because attention is the asset being farmed. So the framework that should protect us from misinformation becomes the vehicle for it. I have watched analysts dismiss on-chain evidence of a drain because narrative momentum was strong. I have watched orderbook DEX promoters claim CEX parity while ignoring the physics that market makers will not post resting quotes on a public chain to be front-run — latency is everything.
During the NFT mania, I ran a podcast called The Digital Soul and interviewed thirty artists and developers in six months. One episode hit fifty thousand downloads in a week. The attention was real; the substance was not always. I burned out and pulled the plug, and I now read that burnout as tuition: analysis can perform the same trick. A deep-dive that moves markets while conveying zero information is not research; it is a second derivative of the hype, dressed in charts.
The deeper point: the medical report's honesty is not humility. It is the most aggressive form of professionalism available. It asserts that the individual case always overrides the standard framework. That is radical in an industry where the standard move is the reverse. We chose rigor in our analytics but not in our epistemology.
The next phase of crypto analysis will not be better AI-generated reports. It will be frameworks comfortable with the phrase: we could not verify this, so we did not score it. Open source is not a license; it's a state of mind. When my team built the Trust Layer framework for EU bank custody, the decisive component was explicit silence — the documented list of what we refused to assert because the evidence was absent.
The Trust Layer rule I insist on: no score without a source, no source without a signature, no signature without a verification trail. As AI-generated analysis floods the feed, the analysts who survive will be the ones who encode N/A as a first-class result — an explicit refusal, not a bug. A model that says we could not verify this is not weak. It is the only model worth owning.
What if every deep-dive opened with its hidden-information table, before the charts and the tokenomics and the moon math? We would lose the theater. We would keep the signal. And we might finally stop mining for truth in the noise of a news cycle that contains none.
